Recent

% | $
Quotes you view appear here for quick access.

Aviv REIT, Inc. Message Board

dobermaniam 10 posts  |  Last Activity: Jun 20, 2016 9:18 AM Member since: Jul 2, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Vascular Biogenics Ltd (NASDAQ:VBLT) Receives Consensus Rating of “Buy” from Brokerages
    Posted by Scott Moore on Jun 17th, 2016 // No Comments
    Vascular Biogenics logoShares of Vascular Biogenics Ltd (NASDAQ:VBLT) have earned a consensus rating of “Buy” from the six brokerages that are presently covering the company. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $14.67.
    VBLT has been the topic of a number of recent research reports. JMP Securities dropped their price objective on shares of Vascular Biogenics from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 9th. Piper Jaffray reaffirmed a “buy” rating and issued a $14.00 price target on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Chardan Capital reaffirmed a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Roth Capital reissued a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 9th.
    Shares of Vascular Biogenics (NASDAQ:VBLT) traded down 2.83% on Friday, reaching $4.46. The company’s stock had a trading volume of 1,195,441 shares. The firm’s 50 day moving average is $3.81 and its 200-day moving average is $3.79. The stock’s market cap is $100.24 million. Vascular Biogenics has a 52-week low of $2.76 and a 52-week high of $12.25.
    Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). On average, equities research analysts forecast that Vascular Biogenics will post ($0.84) EPS for the current year.

  • dobermaniam by dobermaniam Jun 8, 2016 11:49 AM Flag

    The phase 2 news was great! That got the attention of the stock pimps that saw VBLT trade 30 million shares On Momday. The day traders delight de jour ! I'm not hating that, just observing and parking my $ in VBLT.

    Sit back and relax folks, money to be made here. I've been Long 1,700 sh.and holding.

  • dobermaniam dobermaniam Jun 6, 2016 10:04 AM Flag

    Exactly G! And or have a giant pharma come in and buy them out!

  • Reply to

    Buy out Rumor

    by dobermaniam Jun 5, 2016 1:30 PM
    dobermaniam dobermaniam Jun 6, 2016 9:52 AM Flag

    Yes scalp, it's me! Auntie J

  • Reply to

    Monday morning open

    by dobermaniam Jun 5, 2016 9:13 PM
    dobermaniam dobermaniam Jun 6, 2016 9:46 AM Flag

    Tom- first thing you should concern yourself with is actually getting a life.

  • dobermaniam by dobermaniam Jun 5, 2016 9:13 PM Flag

    $6.50 minimum

  • dobermaniam by dobermaniam Jun 5, 2016 1:30 PM Flag

    Will begin this week

  • dobermaniam by dobermaniam Jun 3, 2016 7:59 PM Flag

    Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis DataGlobeNewswire

  • dobermaniam by dobermaniam Jun 3, 2016 7:56 PM Flag

    Could seriously hit $10 next week!

  • Reply to

    Is it the insider sales volume?

    by spinaltap58 May 6, 2016 10:58 AM
    dobermaniam dobermaniam May 6, 2016 11:39 AM Flag

    Most likely lawsuits forcing sale

AVIV
35.250.00(0.00%)Mar 13 4:03 PMEDT